MGF exerts anti-inflammatory effects by inhibiting interleukin-1 receptor-associated kinase 1 (IRAK1) phosphorylation in the mitogen-activated protein kinase (MAPK) and nuclear factor-κB (NF-κB) pathways in C57BL/6 mice with chemically induced inflammatory bowel disease (IBD) with MGF administered at a dose of 50 mg/kg body weight for 10 days. This evidence concerns the gene WNK2 and inflammatory bowel disease.